Targovax OSE TRVX is a clinical-stage biotechnology company focused on developing innovative immune activators to combat hard-to-treat solid tumors. Operating within the immuno-oncology sector, Targovax serves patients with challenging cancer types by enhancing the body's immune response to target and destroy cancer cells. The company's lead product, ONCOS 102, is an oncolytic adenovirus designed to stimulate the immune system and is currently undergoing four clinical trials. Targovax's technology aims to make tumors visible to the immune system, enabling it to recognize and attack patient-specific tumor cells. This approach is based on engineered adenoviruses that kill tumor cells by activating a systemic, patient-specific anti-tumor immune response. The company has demonstrated that combining ONCOS 102 with Keytruda can generate systemic responses that reduce the size of non-injected lesions, known as the abscopal anti-tumor effect. Targovax's business model revolves around the development and clinical testing of its immune activators, with revenue potential from successful commercialization and partnerships. The company primarily targets the oncology market, focusing on innovative cancer treatments that can be used in combination with existing therapies.

Keywords: immuno-oncology, immune activators, solid tumors, ONCOS 102, adenovirus, systemic response, clinical trials, cancer immunotherapy, combination therapy, abscopal effect.